AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAY 8 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) is beginning a formal administrative process to examine the effectiveness of estrogen/androgen combination products for the treatment of hot flashes associated with menopause.
FDA is acting because it does not believe there is substantial evidence that androgens contribute to the effectiveness of these combination products to treat hot flashes in menopausal women who do not find relief from these symptoms when using estrogens alone. Estrogen/androgen combination products were found effective for this indication under a determination FDA made in a 1976 Federal Register notice.
FDA is also offering affected parties the opportunity for a hearing on this issue.
FDA is aware of at least two currently marketed products affected by this proceeding: Estratest and Estratest H.S. Neither of these products has been approved.
It has been FDA's long-standing policy to allow the continued marketing of drug products while matters such as these are being resolved, provided there is no documented serious public health or ...
Source: HighBeam Research, FDA revises finding on estrogen/androgen combination products.